Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating fremanezumab for preventative treatment of migraine in patients with major depressive disorder has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Migraine

Drugs mentioned

• Fremanezumab (fremanezumab)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Migraine, Major Depressive Disorder | Phase 4 | Status: COMPLETED | Results posted: 2023-10-02